Batroxobin is a serin protease that reduces fibronogen levels and is originally extracted from snake venom of Bothrops Atrox. Batroxobin is used in defibrinogenation and thrombolysis and also has an effect on c-fos gene and growth factor.
Batroxobin can efficiently restrain proliferation of VSMCs, by blocking the release and uptake of Ca2+, thus influencing [Ca2+]i.
Batroxobin converts fibrinogen to fibrin through the restricted release of fibrinopeptide-A from fibrinogen to promote blood to clot. Unlike thrombin, it is not affected by heparin and hirudin.
Description: Batroxobin, isolated from Bothrops atrox snake venom, has an Mw of approximately 43kDa.
Physical Appearance: Sterile Filtered white lyophilized powder.
Formulation: The Batroxobin protein was lyophilized from a concentrated (1mg/ml) solution with no additives.
Solubility: It is recommended to reconstitute the lyophilized Batroxobin in sterile 18M-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
Stability: Batroxobin although stable at room temperature for 3 weeks, should be stored below -18°C. Upon reconstitution Batroxobin should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HAS or BSA).
Please prevent freeze-thaw cycles.
Unit Definition: 100BU [Batroxobin Units]=1mg.
